Jump to any asset
850 assets, updated daily
As of September 11, 2026, Gilead Sciences, Inc. (GILD) trades at $144.81. CleaRank Financial AI rates it Hold with a fair value of $144.81, in line with the current price. Wall Street's consensus target is $160.00 across 28 analysts. RSI at 53 is in neutral territory, and the price is above its 50-day average of $137.74.
Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. NASDAQ
$144.81
-0.8400 (-0.58%)
Latest Price
AI Analyst Consensus
55 / 100
Gilead Sciences (GILD) is currently trading at $144.81, with its fair value estimated at the same price, indicating no immediate upside based on this metric. The stock is positioned above its 50-day and 200-day moving averages ($137.74 and $134.65), suggesting a generally positive longer-term trend, though it is currently below its 20-day Exponential Moving Average (EMA), hinting at near-term weakness. Analyst sentiment remains cautiously optimistic, with a median price target of $160.00, implying a 10.5% upside from the current price, and a consensus rating of 'Buy' from 28 analysts. However, significant headwinds are present. The company exhibits heavy insider selling, with $99.9 million in sales versus no reported purchases, signaling a lack of insider confidence. Also, revenue growth is stagnant for the current quarter, projected at 0.00% year-over-year, although modest growth is anticipated in subsequent quarters and for the full year. The company also pays a dividend yield of approximately 2.24%.
GILD Price Analysis
Market Metrics
Open
$145.07
Day Range
$143.67 to $145.91
Prev Close
$145.65
Volume
6.02M
52-Week Range
$108.46 to $157.29
Market Cap
$179.56B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-44%), which may indicate undervaluation or specific company headwinds.
GILD Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, GILD beat estimates 5 times. However, the stock fell 3 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
GILD Analysis
Company's Health
3/5
12-Month Analyst Target
+10.49% Upside
Median of 28 analysts (12-month)
$160.00
AI Technical Analysis
Gilead Sciences (GILD) is trading above its 50-day and 200-day moving averages ($137.74 and $134.65), indicating a generally positive long-term trend, but it is currently below its 20-day EMA, suggesting potential near-term downward pressure. The Relative Strength Index (RSI) is at 53.04, which falls into the neutral momentum category, offering no strong signal of overbought or oversold conditions. Volume has been slightly above average recently, with the latest volume at 6.02 million compared to an average of 5.27 million. Key support levels are around the 50-day SMA of $137.74, while resistance may be encountered near the 20-day EMA of $145.05 and the current price. The MACD indicator is positive at 3.06, suggesting some underlying bullish momentum, but the overall technical picture is mixed due to the price action relative to the shorter-term EMA.
ProTips
- Monitor insider transaction trends closely; the current heavy selling pressure is a significant bearish signal that could precede further price declines.
- Given the negative EPS, investors should scrutinize Gilead's cash flow generation and debt levels to assess the sustainability of its dividend and its ability to fund future research and development.
- Pay close attention to upcoming earnings reports and forward guidance, as any signs of accelerating revenue growth or improved profitability could serve as a catalyst to reverse the current negative sentiment.
Key Catalysts
Bearish
Heavy Insider Selling Pressure
Insiders have sold $99.9 million worth of GILD stock with no reported purchases, indicating a strong bearish sentiment from management and potentially signaling future price weakness.
Source: Insider Trading DataBearish
Negative Earnings Per Share
Gilead Sciences is currently reporting a negative EPS of -$2.65, which raises concerns about the company's profitability and the sustainability of its dividend.
Source: Financial StatementsNeutral
Flat Current Quarter Revenue Growth
Projected revenue growth for the current quarter is 0.00% year-over-year, indicating a lack of immediate top-line expansion, though modest growth is anticipated in subsequent periods.
Source: Wall Street EstimatesBullish
Positive Analyst Price Targets
The median analyst price target for GILD is $160.00, suggesting a potential 10.5% upside from the current price, supported by a 'Buy' consensus from 28 analysts.
Source: Analyst RatingsBullish
Above Key Moving Averages
GILD is trading above its 50-day and 200-day moving averages ($137.74 and $134.65), indicating a generally positive long-term trend and potential support levels.
Source: Technical AnalysisMarket Outlook
The base case outlook for Gilead Sciences (GILD) over the next 6-12 months suggests a period of consolidation or modest recovery, contingent on improved revenue growth and a potential shift in insider sentiment. While analysts have a median price target of $160.00, implying a 10.5% upside, the current fair value aligns with the stock price, limiting immediate gains. The company's ability to translate its pipeline into consistent revenue growth and profitability will be key to driving the stock higher. Potential catalysts for upside include successful clinical trial results or new drug approvals, which could significantly boost investor confidence and revenue streams. Conversely, continued heavy insider selling, persistent negative EPS, or a failure to accelerate revenue growth could lead to a re-evaluation of the stock's valuation, potentially pushing it towards its lower support levels. The sector's average P/E of 31.9 suggests that if GILD can achieve consistent profitability and growth, there is room for valuation expansion.
Key Statistics
| Market Cap | 179.56B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -2.65 |
| Dividend Yield | 2.24% |
| 52 Week High | 157.29 |
| 52 Week Low | 108.46 |
Gilead Sciences (GILD) presents a mixed fundamental picture, with its Price-to-Earnings (P/E) ratio not applicable due to negative Earnings Per Share (EPS) of -$2.65. This indicates the company is currently loss-making on a per-share basis, a significant concern for valuation. The company's Return on Equity (ROE) is also low at 6.9%, below the sector median of 6.9%, suggesting inefficient use of shareholder equity. Revenue growth is projected to be flat at 0.00% for the current quarter, though it is expected to pick up to 3.00% next quarter and 4.00% for the full year. This modest growth is slightly above the sector median revenue growth of 8.1%. The company's dividend yield stands at approximately 2.24%, providing some return to shareholders, but the negative EPS raises questions about the sustainability of this payout without further debt or equity financing.
Earnings & Growth Analysis
Gilead Sciences (GILD) has shown mixed earnings performance recently. The most recent quarter (August 4, 2026) reported an EPS of -$6.75, which was a 6.9% beat against an estimate of -$7.25, though the stock price declined by 2.58%. Prior to that, the May 7, 2026, quarter also saw a beat (2.03 actual vs. 1.91 estimate) but resulted in a price drop of 2.04%. The company did experience a positive price reaction in the February 10, 2026, quarter with a beat and a 5.82% stock increase, and a significant beat in the October 30, 2025, quarter with a 1.14% price gain.
Key Risks
The primary risk for Gilead Sciences (GILD) is the significant insider selling, with nearly $100 million in dispositions and no reported purchases, suggesting a lack of confidence from management. Additionally, the company is currently loss-making with negative EPS of -$2.65, which poses a fundamental risk to its valuation and long-term financial health. Flat revenue growth in the current quarter also presents a near-term challenge, despite modest growth expectations for the remainder of the year.
Technical Indicators
| RSI (14) | 53.04 |
|---|---|
| MACD | 3.06 |
| SMA 50 | 137.74 |
| SMA 200 | 134.65 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($137.74) above the 200-day SMA ($134.65), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.21
Weak correlation
Nasdaq 100 (QQQ)
+0.12
Weak correlation
Bitcoin (BTC)
-0.09
Weak correlation
Gold (XAU)
+0.05
Weak correlation
Check Custom Correlation
Calculating correlation...
GILD Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$143.36
Slight discount to current
Wait for small dip
AGGRESSIVE
$144.81
At current price
Enter now if confident
Risk Management
STOP LOSS
$139.06
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (53.0) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$147.66
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$150.53
+5% (Conservative)
+3.9% (Aggressive)
TARGET 3
$154.83
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for GILD is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in GILD in September 2016 would be worth about $18,365 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in GILD today could grow to about $19,130 by 2036 in the base case, with a bull case near $53,925 and a bear case around $6,787. Projections are statistical simulations, not guarantees.
GILD Stock Price Prediction: 2030
CleaRank's simulation projects a price near $188 for GILD by 2030 in the base case, from $145 today (1.3x over 4 years). The downside path ends near $97.46. These are outcomes of a Monte Carlo simulation run on GILD's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $111 | $155 | $214 |
| 2028 | $104 | $165 | $262 |
| 2029 | $99.72 | $176 | $310 |
| 2030 | $97.46 | $188 | $362 |
| 2031 | $96.25 | $200 | $417 |
| 2032 | $95.77 | $214 | $477 |
| 2033 | $95.82 | $228 | $543 |
| 2034 | $96.30 | $243 | $615 |
| 2035 | $97.14 | $260 | $694 |
| 2036 | $98.28 | $277 | $781 |
Method: 10,000 simulated price paths using GILD's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
GILD Insider Trading Analysis
Bought
None
No open-market buys
Sold
$99.9M
59 Transactions
Insiders
15
Active Traders
Avg Transaction
$1.7M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 29, 2024 | DICKINSON ANDREW D
Chief Financial Officer
|
Sell | 248.6K | $23.1M |
| Feb 5, 2026 | O'DAY DANIEL PATRICK
Chief Executive Officer
|
Sell | 115.6K | $17.3M |
| Jan 23, 2026 | O'DAY DANIEL PATRICK
Chief Executive Officer
|
Sell | 115.6K | $15.6M |
| Nov 27, 2024 | PARSEY MERDAD V
Officer
|
Sell | 164.2K | $15.1M |
| Feb 12, 2025 | DICKINSON ANDREW D
Chief Financial Officer
|
Sell | 137.7K | $14.1M |
| Jan 31, 2025 | DICKINSON ANDREW D
Chief Financial Officer
|
Sell | 142.2K | $13.8M |
| Nov 12, 2025 | TELMAN DEBORAH H
General Counsel
|
Sell | 53.6K | $6.6M |
| Feb 17, 2026 | MERCIER JOHANNA
Officer
|
Sell | 28.0K | $4.3M |
| Aug 17, 2026 | MERCIER JOHANNA
Officer
|
Sell | 28.0K | $3.9M |
| May 15, 2026 | MERCIER JOHANNA
Officer
|
Sell | 28.0K | $3.7M |
Page 1 of 1
Frequently Asked Questions
What is Gilead Sciences' (GILD) current stock price and fair value?
Gilead Sciences (GILD) is currently trading at $144.81. Based on the provided fair value metric, the stock is not indicating any immediate upside, as the fair value is also estimated at $144.81.
Is Gilead Sciences (GILD) stock a buy right now?
Gilead Sciences (GILD) has a 'Hold' consensus rating from our AI analysis, with a consensus score of 55. Wall Street analysts have a more positive 'Buy' consensus with a score of 72, and a median price target of $160.00, suggesting a 10.5% upside. However, significant insider selling and negative EPS warrant caution.
What are the biggest risks facing Gilead Sciences (GILD)?
The most significant risks for Gilead Sciences (GILD) include substantial insider selling totaling $99.9 million, negative EPS of -$2.65 indicating current unprofitability, and flat revenue growth in the most recent quarter. These factors collectively present considerable headwinds.
How is Gilead Sciences (GILD) performing in terms of revenue growth compared to its peers?
Gilead Sciences (GILD) is projected to have flat revenue growth (0.00%) for the current quarter, which is below the sector median of 8.1%. While growth is expected to improve in subsequent quarters and for the full year, the current stagnation is a concern.
What is the analyst price target for Gilead Sciences (GILD)?
The median analyst price target for Gilead Sciences (GILD) is $160.00, with a high of $180.00 and a low of $123.00. This implies an upside potential of 10.5% from the current stock price of $144.81.
What is Gilead Sciences' (GILD) dividend yield and is it sustainable?
Gilead Sciences (GILD) offers a dividend yield of approximately 2.24%. Given the company's current negative EPS of -$2.65, the sustainability of this dividend without impacting future growth or requiring additional financing should be carefully monitored.
What does the insider trading activity suggest about Gilead Sciences (GILD)?
Insider trading activity for Gilead Sciences (GILD) indicates heavy selling pressure, with $99.9 million in total sales and no reported purchases. This heavy insider selling verdict suggests a lack of confidence from insiders and is a notable bearish indicator.
What is Gilead Sciences' (GILD) stock forecast for 2030?
Based on Monte Carlo simulations, Gilead Sciences' (GILD) stock forecast for 2030 shows a base case price of $187.71, a downside projection of $97.46, and an upside potential of $361.52. These figures represent statistical outcomes, not guaranteed price targets.